# Artivion, Inc.: overview

AORT · NYSE · CIK 784199 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aort.md) · [Financials](/companies/aort/financials.md) · [Filings](/companies/aort/filings.md) · [Insiders](/companies/aort/insiders.md)

Latest reported revenue: [$125.8m](/filings/0001628280-26-054746.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-054746).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [95.8](/filings/0001628280-25-050502.md) | [97.3 d](/filings/0001628280-26-009046.md) | [99.0](/filings/0001628280-26-032620.md) | [113](/filings/0001628280-26-054746.md) | [113](/filings/0001628280-25-050502.md) | [116 d](/filings/0001628280-26-009046.md) | [116](/filings/0001628280-26-032620.md) | [126](/filings/0001628280-26-054746.md) |
| Gross margin | % | [63.7%](/filings/0001628280-25-050502.md) | [63.2% d](/filings/0001628280-26-009046.md) | [64.2%](/filings/0001628280-26-032620.md) | [64.7%](/filings/0001628280-26-054746.md) | [65.6%](/filings/0001628280-25-050502.md) | [63.1% d](/filings/0001628280-26-009046.md) | [64.9%](/filings/0001628280-26-032620.md) | [64.0%](/filings/0001628280-26-054746.md) |
| Operating margin | % | [4.6%](/filings/0001628280-25-050502.md) | [2.7% d](/filings/0001628280-26-009046.md) | [2.2%](/filings/0001628280-26-032620.md) | [7.4%](/filings/0001628280-26-054746.md) | [11.1%](/filings/0001628280-25-050502.md) | [9.2% d](/filings/0001628280-26-009046.md) | [5.0%](/filings/0001628280-26-032620.md) | [(6.7%)](/filings/0001628280-26-054746.md) |
| Net margin | % | [(2.4%)](/filings/0001628280-25-050502.md) | [(16.9%) d](/filings/0001628280-26-009046.md) | [(0.5%)](/filings/0001628280-26-032620.md) | [1.2%](/filings/0001628280-26-054746.md) | [5.7%](/filings/0001628280-25-050502.md) | [2.1% d](/filings/0001628280-26-009046.md) | [1.2%](/filings/0001628280-26-032620.md) | [(10.7%)](/filings/0001628280-26-054746.md) |
| Diluted EPS | $ per share | [(0.05)](/filings/0001628280-25-050502.md) | not reported | [(0.01)](/filings/0001628280-26-032620.md) | [0.03](/filings/0001628280-26-054746.md) | [0.13](/filings/0001628280-25-050502.md) | not reported | [0.03](/filings/0001628280-26-032620.md) | [(0.28)](/filings/0001628280-26-054746.md) |
| Free cash flow | $m | [7.8 d](/filings/0001628280-25-050502.md) | [8.7 d](/filings/0001628280-26-009046.md) | [(20.6)](/filings/0001628280-26-032620.md) | [11.7 d](/filings/0001628280-26-054746.md) | [17.7 d](/filings/0001628280-25-050502.md) | [(7.9) d](/filings/0001628280-26-009046.md) | [(6.8)](/filings/0001628280-26-032620.md) | [(12.0) d](/filings/0001628280-26-054746.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [299](/filings/0000784199-24-000033.md) | [314](/filings/0000784199-25-000029.md) | [354](/filings/0001628280-26-009046.md) | [389](/filings/0001628280-26-009046.md) | [441](/filings/0001628280-26-009046.md) |
| Gross margin | % | [66.1%](/filings/0000784199-24-000033.md) | [64.5%](/filings/0000784199-25-000029.md) | [64.7%](/filings/0001628280-26-009046.md) | [64.0%](/filings/0001628280-26-009046.md) | [64.4%](/filings/0001628280-26-009046.md) |
| Operating margin | % | [2.7%](/filings/0000784199-24-000033.md) | [2.0%](/filings/0000784199-25-000029.md) | [1.6%](/filings/0001628280-26-009046.md) | [10.0%](/filings/0001628280-26-009046.md) | [7.6%](/filings/0001628280-26-009046.md) |
| Net margin | % | [(5.0%)](/filings/0000784199-24-000033.md) | [(6.1%)](/filings/0000784199-25-000029.md) | [(8.7%)](/filings/0001628280-26-009046.md) | [(3.4%)](/filings/0001628280-26-009046.md) | [2.2%](/filings/0001628280-26-009046.md) |
| Diluted EPS | $ per share | [(0.38)](/filings/0000784199-24-000033.md) | [(0.48)](/filings/0000784199-25-000029.md) | [(0.75)](/filings/0001628280-26-009046.md) | [(0.32)](/filings/0001628280-26-009046.md) | [0.21](/filings/0001628280-26-009046.md) |
| Free cash flow | $m | [(15.7)](/filings/0000784199-24-000033.md) | [(15.9)](/filings/0000784199-25-000029.md) | [9.1](/filings/0001628280-26-009046.md) | [11.0](/filings/0001628280-26-009046.md) | [0.8](/filings/0001628280-26-009046.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/aort/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $150.0m | 6,674,017 |  | Added +199,163 |
| [NOMURA ASSET MANAGEMENT INTERNATIONAL INC.](/funds/921739.md) | 2026-06-30 | $71.6m | 3,184,974 |  | Added +728,828 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $57.5m | 2,557,961 |  | Added +288,667 |
| [Juniper Investment Company, LLC](/funds/1794034.md) | 2026-06-30 | $45.4m | 2,019,885 |  | Added +830,749 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $45.0m | 2,004,619 |  | Added +52,611 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $44.1m | 1,963,471 |  | Reduced −619,956 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $41.8m | 1,858,051 |  | Added +175,778 |
| [Ophir Asset Management Pty Ltd](/funds/1844640.md) | 2026-06-30 | $40.4m | 1,800,008 |  | Added +849,158 |
| [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $39.0m | 1,737,290 |  | Added +100,000 |
| [Conestoga Capital Advisors, LLC](/funds/1163744.md) | 2026-06-30 | $36.5m | 1,623,700 |  | Added +448,290 |

## Recent filings

[All 1,684 filings](/companies/aort/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-07 | 13:57 ET | [10-Q](/filings/0001628280-26-054746.md) | Quarterly report, period 2026-06-30 | 0001628280-26-054746 |
| 2026-08-06 | 16:08 ET | [8-K](/filings/0001628280-26-054294.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-054294 |
| 2026-05-18 | 07:06 ET | [8-K](/filings/0001628280-26-035798.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-035798 |
| 2026-05-15 | 15:13 ET | [8-K](/filings/0001628280-26-035507.md) | 5.07 Shareholder vote results | 0001628280-26-035507 |
| 2026-05-08 | 10:56 ET | [10-Q](/filings/0001628280-26-032620.md) | Quarterly report, period 2026-03-31 | 0001628280-26-032620 |
| 2026-05-07 | 16:10 ET | [8-K](/filings/0001628280-26-032097.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-032097 |
| 2026-04-01 | 16:18 ET | [DEF 14A](/filings/0001999371-26-007510.md) | Proxy statement, period 2026-05-12 | 0001999371-26-007510 |
| 2026-02-18 | 16:14 ET | [10-K](/filings/0001628280-26-009046.md) | Annual report, period 2025-12-31 | 0001628280-26-009046 |
| 2026-02-12 | 16:10 ET | [8-K](/filings/0001628280-26-007674.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-007674 |
| 2025-11-07 | 11:41 ET | [10-Q](/filings/0001628280-25-050502.md) | Quarterly report, period 2025-09-30 | 0001628280-25-050502 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-009046.md), filed Feb 18, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ff6990ca-23c1-49ee-96e0-07564278a24b)

## About the filer

- CIK: 784199
- Tickers: AORT
- Exchange: NYSE
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:31 ET. No prices; not investment advice.